Envoy Medical said it has regained compliance with Nasdaq’s continued listing requirement after previously falling below the minimum $35 million Market Value of Listed Securities threshold under Nasdaq Listing Rule 5550(b)(2). The company reported it addressed the issue through alternatives permitted under Rule 5550(b) and expects to maintain its listing on the Nasdaq Capital Market.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Envoy Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-021116), on February 27, 2026, and is solely responsible for the information contained therein.